guiding you onto the right path

Job Search

Job Title
Location
Sector
Job Type
Minimum Salary (£)

Latest Jobs

CONSULTANT SENIOR CONSULTANT
Purpose: Acting as the key interface with clients over projects, manages the timely delivery of project outputs in line with client expectations. Dev...
SENIOR ASSOCIATE
Purpose: Manages the delivery of client project(s), ensuring delivery of the project in line with client objectives and expectations as well as proje...

Senior Market Access Writer

This role will work as part of a team of writers on the following market access projects for global pharmaceutical clients:

 

  • Value Dossiers and value stories to support the case for new products
  • Literature reviews to inform clinical trial and economic model design
  • Analyses of the pricing, reimbursement and competitive landscapes
  • Reports from payer advisory boards

 

The Senior Market Access Writer position is ideal for someone already working in market access looking for the next move, or for an established medical communications writer seeking an opportunity to develop a career in market access.

 

  • Cataloging client-supplied source materials and management of references
  • Undertaking literature reviews
  • Writing fully-referenced content
  • Developing simple visuals and graphics
  • Editing, quality assurance and formatting
  • Working effectively with other members of the writing team and the Project Director
  • Project management
  • Client contact through teleconferences and face-to-face meetings
  • Travel required: 0-5%

 

Essential

 

  • Some experience in agency or consultancy environment in a medical writing role
  • Technical writing skills balanced with ability to clearly convey complex information
  • Ability to understand and synthesise clinical, economic and commercial information
  • Research and analysis skills e.g. ability to undertake reviews of the scientific literature
  • Organisational skills to manage projects or project modules independently
  • Ability to rapidly absorb information on different diseases and therapy areas
  • Comfort in a client-facing role
  • Ability to work on own initiative, prioritise and work to deadlines
  • Fluent written and spoken English
  • MS Word, PowerPoint, Excel
Job Type:
Permanent
Experience:
PhD
Location:
London
Sector:
Market Access & Pricing Reimbursement
Salary:
£Negotiable
Ref:
1001

How to apply

Apply Now

Latest News

Penn engineers turn toxic fungus into anti-cancer compound
Fri, 27 Jun 2025 10:00:00 +0200
Penn-led researchers have turned a deadly fungus into a potent cancer-fighting compound. After isolating a new class of molecules from Aspergillus flavus, a toxic crop fungus linked to deaths in the excavations of ancient tombs, the researchers modified the chemicals and tested them against leukemia cells. The result? A promising cancer-killing compound that rivals FDA-approved drugs and opens up new frontiers in the discovery of more fungal medicines.
New drug for diabetes and obesity shows promising results
Thu, 26 Jun 2025 10:00:00 +0200
Lower blood sugar and increased fat burning - without negatively affecting appetite or muscle mass. These are some of the most promising effects of a new potential drug treatment for people with type 2 diabetes and obesity, according to a new study published in the journal Cell by researchers from Karolinska Institutet and Stockholm University.
Article presents innovative drug for controlling weight and blood sugar
Wed, 25 Jun 2025 10:00:00 +0200
An article published in the journal Nature Metabolism presents an experimental drug that stimulates adipose tissue cells to produce heat through a process known as thermogenesis, thereby promoting weight loss. In animal tests, the compound prevented fat accumulation in response to a high-fat diet, treated existing obesity, and reversed associated metabolic disorders, including insulin resistance.
Weekly semaglutide improves blood sugar and weight in adults with Type 1 diabetes
Tue, 24 Jun 2025 10:00:00 +0200
A new clinical trial found that taking a popular diabetes and weight-loss drug once weekly significantly improves blood sugar and leads to substantial weight loss in adults with Type 1 diabetes who use automated insulin delivery systems.

The results were published in the journal NEJM Evidence.

Targeting fusion protein's role in childhood leukemia produces striking results
Mon, 23 Jun 2025 10:00:00 +0200
Scientists at St. Jude Children's Research Hospital and Dana-Farber Cancer Institute today report the identification of a novel combination therapy approach to treat pediatric acute myeloid leukemia (AML). Standard treatment is often ineffective against AML, a cancer that commonly relapses with poor prognosis, particularly when the disease is fueled by fusion proteins involving NUP98.
AI could accelerate protein engineering - key for developing new medicines
Fri, 20 Jun 2025 10:00:00 +0200
In a study published in the journal Nature Machine Intelligence, Sheffield computer scientists in collaboration with AstraZeneca and the University of Southampton have developed a new machine learning framework that has shown the potential to be more accurate at inverse protein folding than existing state-of-the-art methods.
AstraZeneca enters strategic collaboration with CSPC Pharmaceuticals focused on AI-enabled research
Thu, 19 Jun 2025 10:00:00 +0200
AstraZenecaAstraZeneca has entered a strategic research collaboration with Shijiazhuang City-based CSPC Pharmaceuticals Group Limited. Working together on high priority targets, the collaboration aims to advance the discovery and development of novel oral candidates, with the potential to treat diseases across multiple indications.
Researchers identify a protein that may help improve the treatment of obesity and cardiovascular disease
Wed, 18 Jun 2025 10:00:00 +0200
Obesity, diabetes and cardiovascular diseases are increasingly present in the population. Brown adipose tissue has a protective function against these prevalent diseases, as it burns calories and can produce body heat from fat. But as the body ages, the activity of brown adipose tissue decreases. This inactivation of brown adipose tissue - also typical of obese people - remains poorly studied in the scientific literature.
New strategy for the treatment of severe childhood cancer
Tue, 17 Jun 2025 10:00:00 +0200
Researchers at Karolinska Institutet and Lund University in Sweden have identified a new treatment strategy for neuroblastoma, an aggressive form of childhood cancer. By combining two antioxidant enzyme inhibitors, they have converted cancer cells in mice into healthy nerve cells. The study is published in the journal Proceedings of the National Academy of Sciences (PNAS).
Groundbreaking TACIT algorithm offers new promise in diagnosing, treating cancer
Mon, 16 Jun 2025 10:00:00 +0200
Researchers at VCU Massey Comprehensive Cancer Center have developed a novel algorithm that could provide a revolutionary tool for determining the best options for patients - both in the treatment of cancer and in the prescription of medicines. As recently published in Nature Communications, Jinze Liu, Ph.D., and Kevin Byrd, D.D.S., Ph.D., created Threshold-based Assignment of Cell Types from Multiplexed Imaging Data (TACIT), which assigns cell identities based on cell-marker expression profiles.
Smartphone tests could accelerate drug development for Huntington's disease
Fri, 13 Jun 2025 10:00:00 +0200
A series of digital tests, carried out via a smartphone app, could enhance the detection of disease progression in Huntington's disease and improve the efficiency of clinical trials, finds research led by scientists at University College London (UCL) and Roche.

The research, published in Brain, highlights how digitising tests designed to measure the progression of motor symptoms in people with Huntington's disease can provide a sensitive and reliable way to track changes in the function of patients.

Vividion Therapeutics and Bayer further strengthen oncology development pipeline with clinical-stage WRN inhibitor
Thu, 12 Jun 2025 10:00:00 +0200
BayerVividion Therapeutics, Inc. (Vividion), a clinical-stage biopharmaceutical company, and a wholly owned and independently operated subsidiary of Bayer AG, announced it has secured exclusive worldwide rights to develop and commercialize the clinical-stage Werner helicase (WRN) covalent inhibitor VVD-214 (RO7589831), strengthening and complementing its innovative oncology development pipeline. VVD-214 was discovered and developed under an exclusive worldwide collaboration and license agreement initiated between Vividion and Roche in 2020.
Ultra-selective aptamers give viruses a taste of their own medicine
Wed, 11 Jun 2025 10:00:00 +0200
We have all heard of antibodies - proteins produced by our bodies to bind to viruses or bacteria, marking them for elimination by the immune system. But not all of us are familiar with aptamers: short segments of DNA or RNA that are designed to bind, like antibodies, to specific targets. Synthetic and inexpensive to produce, aptamers are attractive alternatives to antibodies for biomedical diagnostics and therapeutics.
Fermenting legume pulses boosts their antidiabetic, antioxidant properties
Tue, 10 Jun 2025 10:00:00 +0200
Food scientists at the University of Illinois Urbana-Champaign identified the optimal fermentation conditions for pulses - the dried edible seeds of legumes - that increased their antioxidant and antidiabetic properties and their soluble protein content.

Using the bacteria Lactiplantibacillus plantarum 299v as the microorganism, the team fermented pulses obtained from varying concentrations of black bean, black-eyed pea, green split pea, red lentil and pinto bean flours.

Improving T cell responses to vaccines
Mon, 09 Jun 2025 10:00:00 +0200
In the quest to design vaccines that better help the body's immune system fight disease, scientists are always looking for more tools for their arsenal. The strong antibody responses generated by vaccines provide an important first round of defense, but "you always want to have a backup plan," says Biomedical Graduate Studies Ph.D. student Emily A. Aunins, considering viruses mutate to evade antibody responses that become widespread in a population.
ISTH: new data highlight innovation from Sanofi's pipeline in rare diseases
Fri, 06 Jun 2025 10:00:00 +0200
SanofiNew data from 18 abstracts, including five oral presentations, will be presented at the 33rd congress of the International Society on Thrombosis and Haemostasis (ISTH) in Washington D.C., US from June 21 to 25, 2025, highlighting Sanofi as a leader in hemophilia committed to rare blood diseases. Data to be presented expand on the potential of rilzabrutinib to address the underlying immune dysregulation of immune thrombocytopenia (ITP) and strengthen Sanofi as a leader in hemophilia with ALTUVIIIO and the newly launched Qfitlia, aimed at providing more treatment options to help improve patients' lives.
Fighting myeloma with fiber: Plant-based diet offers promise
Thu, 05 Jun 2025 10:00:00 +0200
Results from a new clinical trial suggest that a high-fiber plant-based diet could benefit patients at risk for developing multiple myeloma, the second most common type of blood cancer. The study showed that the diet was not only feasible and well-received but also improved several factors that could potentially delay the progression of precancerous conditions that can lead to multiple myeloma.
Collaborations result in antibiotic resistance breakthrough
Wed, 04 Jun 2025 10:00:00 +0200
University of Otago - Ōtākou Whakaihu Waka researchers have been part of two groundbreaking studies in the battle against drug resistant strains of Mycobacterium tuberculosis, the cause of tuberculosis.

Co-author on both studies, Dr Matthew McNeil, of the Department of Microbiology and Immunology, describes tuberculosis as a "massive public health problem" that is challenging to solve.

Tea, berries, dark chocolate and apples could lead to a longer life span
Tue, 03 Jun 2025 10:00:00 +0200
New research has found that those who consume a diverse range of foods rich in flavonoids, such as tea, berries, dark chocolate, and apples, could lower their risk of developing serious health conditions and have the potential to live longer.

The study was led by a team of researchers from Queen's University Belfast, Edith Cowan University Perth (ECU), and the Medical University of Vienna.

Application of machine learning in drug side effect prediction: databases, methods and challenges
Mon, 02 Jun 2025 10:00:00 +0200
Understanding and preventing drug side effects holds a profound influence on drug development and utilization, profoundly impacting patients' physical and mental well-being. Traditional artificial drug experimentation methods are not only expensive but also time-consuming, rendering comprehensive testing a challenging task.

Upload Your CV

Need help finding that new job? Leave your details with us and request a call back from one of our consultants.

Submit A Vacancy

Looking to expand? Or a vacancy has become available in your business then let us know and we can find the right person for you